Omeros (OMER) reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart ...

Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the ...

The Company filed an amended and restated preliminary short form prospectus (the " A&R Prospectus ”) on March 20, 2025 with ...

The abnormal accumulation of extravascular fluid, pulmonary edema settles in the lung interstitium and alveoli. There, it ...

T45 Labs announced the close of its $25 million T45 Fund I. The fund will advance and fuel development and clinical research prog ...

EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With ...

DelveInsight's "EMPAVELI Market Size, Forecast, and Market Insight Report" highlights the details around EMPAVELI, a ...

A LARGE multinational study has revealed that patients with diabetes mellitus (DM) face significantly worse long-term outcomes following percutaneous coronary intervention (PCI) for coronary ...

The Javelin IVL catheter "has the ability to transform the way that physicians are able to treat patients,” Shockwave CMO Dr. Nick West said.

Researchers at the Netherlands Institute for Neuroscience have collaborated with several universities to develop a new ...

Michael Bromberg, MD, PhD, talks with Physician’s Weekly about renal disease in patients with paroxysmal nocturnal ...